Join our Free Newsletter and unlock 50% off AltIndexFree newsletter + 50% offJoin free

Did Vivos Therapeutics Beat Earnings?

Vivos Therapeutics (VVOS) reported Q2 '26 revenue of $5.2M, up 34.9% year-over-year.

AltIndex tracks earnings alongside 25+ alternative data signals that can move ahead of the report — Vivos Therapeutics’s job postings, web traffic, and employee business outlook. See the full VVOS stock analysis or the earnings calendar for upcoming reports.

Vivos Therapeutics Quarterly Financial Trends ()

MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Revenue3.9M3.7M3M3.8M6.8M3.8M5.1M5.2M
Gross margin60.5%56.7%50.0%55.2%58.0%78.1%50.7%57.3%
Operating margin-68.5%-75.9%-129.9%-127.4%-69.8%-166.9%-128.7%-83.7%
Net income-2.6M-2.8M-3.9M-5M-5.4M-7M-7.8M-5.5M
Net margin-67.8%-76.4%-128.1%-131.2%-79.6%-181.9%-150.8%-106.4%
EPS————————

Vivos Therapeutics Earnings Trend Analysis

Over the eight quarters from Q3 '24 to Q2 '26, Vivos Therapeutics’s quarterly revenue moved from $3.9M to $5.2M. Net margin compressed from -67.8% to -106.4%, against a 57.3% gross margin in the most recent quarter — a read on whether revenue growth is translating into profit.

When Is Vivos Therapeutics’s Next Earnings Date?

Vivos Therapeutics reports earnings on a quarterly schedule. Its most recent report covered Q2 '26. For the confirmed upcoming date — and every other company reporting soon — see the VVOS earnings calendar.

Frequently Asked Questions: Vivos Therapeutics Earnings

Vivos Therapeutics's next earnings date has not been confirmed yet. See the earnings calendar for all upcoming reports.

Vivos Therapeutics reported Q2 '26 revenue of $5.2M, up 34.9% from the same quarter a year earlier.

Signals like job postings, web traffic, and employee sentiment reflect business activity in real time and can move before quarterly results are reported. AltIndex combines them with 25+ others in the VVOS AI Score.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.